الفهرس 
Title: Detection of c-x-c chemokine receptor type 5 gene polymorphisms in Egyptian non-hodgkin lymphoma patients
AbstractOnly 14 pages are availabe for public view
 |  | from | 216 |  |  |
| | | from | 216 | | |
Abstract
The chemokine receptor CXCR5 is selectively expressed on B cells and it is involved in lymphocyte homing and the development of normal lymphoid tissue. Its principle ligand is CXCL13 or B lymphocyte chemoattractant (BLC). Three polymorphisms in CXCR5 gene, rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A, have been identified in CXCR5 gene. The aim of the work is to study the expression and to assess the impact of genetic polymorphisms of CXCR5 on the susceptibility and response to therapy of non-Hodgkin lymphoma (NHL). Fifty patients with NHL as well as fifty healthy control subjects are included in this study. CXCR5 rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A genotypes were determined by PCR-RFLP. Our study revealed that both CXCR5 rs148351692 C/G, rs6421571 C/T gene polymorphisms are associated with increased risk of developing NHL with OR=29.57 (95% CI=8.96-97.56) and 4.45 (95% CI=1.68-11.81) respectively, while CXCR5 rs78440425 G/A showed no statistical significant difference between NHL patients and the control group regarding the risk of developing NHL. Moreover, the double and triple combined gene polymorphisms are associated with about 129 fold and 108 fold respectively increased risk of developing NHL. In conclusion, CXCR5 rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A gene polymorphisms could be involved in the pathophysiology and development of NHL. They may be useful as predictive molecular markers for prognosis and disease outcome in NHL patients